{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A dose escalation Phase I clinical trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with suspected stage I/II NSCLC"
      },
      "Intervention": {
        "score": 2,
        "evidence": "NIR imaging following peritumoral injection of 3.8 \u2013 2500 \u03bcg indocyanine green (ICG)"
      },
      "Objective": {
        "score": 1,
        "evidence": "Our objective was to perform a dose escalation study to assess safety and feasibility of intraoperative near-infrared (NIR) fluorescence imaging"
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "Visualization of lymphatic migration, SLN identification, and adverse events were recorded."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Thirty eight patients underwent ICG injection and NIR imaging"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "SLN identification increased with ICG dose with <25% SLN detected in dose cohorts \u2264600ug vs 89% success at \u22651000 \u03bcg."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse reactions were noted."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 11,
    "max_score": 25
  },
  "model": "gpt-4o"
}